Participant flow



Baseline characteristics

Demographic data	**Enrolled set/Safety set/PK set/PD set - N=16**
Gender	
Male – n (%)	16 (100)
Age (years)	
Mean ± SD	36.4±13.7
Median (range)	37.5 (18 – 54)
Body weight (kg)	
Mean ± SD	78.65±10.30
Range	78.50 (59.2 – 100.2)
Height (cm)	
Mean ± SD	179.1±7.7
Median (range)	178 (170 – 196)
BMI (kg/m^2)	
Mean ± SD	24.49±2.59
Median (range)	24.65 (18.9 – 28.2)
Race	
White – n (%)	15 (93.75)
Other, Mulatto – n (%)	1 (6.25)

Outcome measures

Primary outcome

Losartan and EXP3174 (active carboxylic metabolite) - Statistical test results. N=16

Losartan				
PK parameter	**Losartan potassium 100 mg**	**Cozaar® 100 mg**	**Point estimate (%)**	**Confidence intervals (%)**
C_{max} (ng/mL)	174.48±96.89	465.54±205.21	35.04	25.67 - 47.84
t_{max} (h)	1.50 (0.50-6.00)	1.00 (0.50-4.00)	-	-
AUC_{0-t} (h*ng/mL)	431.68±170.48	742.45±241.60	56.11	50.90 - 61.87
$AUC_{0-\infty}$ (h*ng/mL)	454.67±171.68	742.92±219.28	59.25	53.95 - 65.06
$t_{1/2}$ (h)	2.15±0.66	2.23±0.49	-	-

Values are arithmetic means ± SD, except for t_{max}: median (min-max)

EXP3174				
PK parameter	**Losartan potassium 100 mg**	**Cozaar® 100 mg**	**Point estimate (%)**	**Confidence intervals (%)**
Cmax (ng/mL)	351.98±157.28	750.93±302.82	46.15	41.47 - 51.35
tmax (h)	5.00 (1.50-8.00)	2.50 (2.00-5.00)	-	-
AUC0-t (h*ng/mL)	2557.71±1045.08	4389.99±1660.98	56.79	50.70 - 63.60
AUC0-∞ (h*ng/mL)	2816.25±1137.84	4653.99±1804.28	59.06	52.22 - 66.81
t1/2 (h)	4.63±1.54	4.08±1.23	-	-

Values are arithmetic means ± SD, except for t_{max}: median (min-max)

Secondary outcome

Mean ± SD **aldosterone** plasma concentrations (ng/L) at pre-dose and up to 24 h post-dose after single dose administration of Losartan potassium 100 mg modified-release tablets (Test) and Cozaar® 100 mg losartan potassium film-coated tablets. PD set

Time		**Aldosterone plasma concentrations (ng/L) - Mean±SD**	
		Test - N=16	**Reference - N=16**
Pre-dose	0	82.64±48.39	77.07±18.83
Post-dose	3 h	67.83±35.87	62.82±57.57
	6 h	49.20±24.54	44.73±17.72
	9 h	64.81±33.57	57.05±25.44
	12 h	50.20±24.11	47.09±19.49
	16 h	53.48±47.36	47.19±22.15
	24 h	83.23±37.02	78.18±37.95

Test: Losartan potassium 100 mg modified-release tablets; Reference: Cozaar® 100 mg losartan potassium film-coated tablets

Mean ± SD **PRA** plasma concentrations (mU/L) at pre-dose and up to 24 h post-dose after single dose administration of Losartan potassium 100 mg modified-release tablets (Test) and Cozaar® 100 mg losartan potassium film-coated tablets. PD set

Time (h)		**PRA plasma concentrations (mU/L) - Mean±SD**	
		Test - N=16	**Reference - N=16**
Pre-dose	0	9.59±5.75	10.43±4.07
Post-dose	3 h	19.50±19.65	27.08±24.67
	6 h	105.21±82.33	147.93±129.65
	9 h	74.76±74.57	83.69±80.61
	12 h	24.09±24.34	27.15±26.30
	16 h	24.06±26.29	24.93±22.80
	24 h	24.75±31.53	19.08±16.91

Test: Losartan potassium 100 mg modified-release tablets; Reference: Cozaar® 100 mg losartan potassium film-coated tablets

Mean ± SD **angiotensin II** plasma concentrations (pg/mL) at pre-dose and up to 24 h post-dose after single dose administration of Losartan potassium 100 mg modified-release tablets (Test) and Cozaar® 100 mg losartan potassium film-coated tablets. PD set

Time		**Angiotensin II plasma concentrations (pg/mL) - Mean±SD**	
		Test - N=16	**Reference - N=16**
Pre-dose	0	7.8±2.8	7.9±2.8
Post-dose	3 h	12.4±10.2	16.8±13.1
	6 h	42.6±37.0	62.6±51.2
	9 h	28.9±24.7	34.1±28.5
	12 h	11.7±7.4	12.3±8.1
	16 h	11.9±8.9	12.3±6.8
	24 h	10.3±9.4	10.1±7.4

Test: Losartan potassium 100 mg modified-release tablets; Reference: Cozaar® 100 mg losartan potassium film-coated tablets

Mean ± SD **vital signs** values at pre-dose and up to 24 h post-dose after single dose administration of Losartan potassium 100 mg modified-release tablets (Test) and Cozaar® 100 mg losartan potassium film-coated tablets. PD set

Time (h)		**Test - N 16**			**Reference - N 16**		
		SBP	**DBP**	**HR**	**SBP**	**DBP**	**HR**
Pre-dose	0	115.8±8.1	70.6±6.8	64.7±8.0	115.0±7.6	73.0±7.9	61.1±7.6
Post-dose	3 h	112.9±6.5	78.9±6.7	58.5±7.1	112.6±8.3	78.1±7.3	59.4±10.0
	6 h	116.3±9.1	68.4±10.1	75.3±8.6	114.4±8.9	67.3±12.3	72.0±9.7
	9 h	109.4±7.3	68.5±6.4	71.5±10.8	110.6±9.4	66.3±7.4	69.1±10.6
	12 h	114.0±7.6	71.0±8.3	65.8±7.4	115.5±6.3	73.0±6.4	64.7±9.8
	16 h	113.4±9.3	69.0±7.3	66.9±6.5	109.9±8.0	67.1±6.5	63.4±9.3
	24 h	117.9±7.7	75.9±8.1	63.1±9.0	114.1±8.7	70.9±7.3	62.4±5.8

Test: Losartan potassium 100 mg modified-release tablets; Reference: Cozaar® 100 mg losartan potassium film-coated tablets; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate

Adverse events

Overview of TEAEs. Safety set. N=16

Category	Test - N=16		Reference - N=16		Overall - N=16	
	N AE	**n (%)**	**N AE**	**n (%)**	**N AE**	**n (%)**
All TEAEs	0	0 (0.0)	1	1 (6.3)	1	1 (6.3)
Related	0	0 (0.0)	1	1 (6.3)	1	1 (6.3)
Not related	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
Leading to discontinuation	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
SAEs	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)

Test: Losartan 100 mg (T); Reference: Cozaar® 100 mg (R)

Number of TEAEs and number of subjects with TEAEs by System Organ Class (SOC), preferred term (PT) and treatment. Safety set. N=16

System Organ Class	Test - N=16		Reference - N=16		Overall - N=16	
Preferred term	N AEs	n (%) Subj	N AEs	n (%) Subj	N AEs	n (%) Subj
All TEAEs – all SOCs	0	0 (0.0)	1	1 (6.3)	1	1 (6.3)
Gastrointestinal disorders	0	0 (0.0)	1	1 (6.3)	1	1 (6.3)
Nausea	0	0 (0.0)	1	1 (6.3)	1	1 (6.3)

MedDRA version 23.0; Test: Losartan 100 mg (T); Reference: Cozaar® 100 mg (R)